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Abstract The current study was designed to determine the
beneficial effects of zinc supplementation on expressed levels
of peroxisome proliferator-activated receptor gamma (PPAR-γ)
and glucose transporter type 1 (GLUT1) genes in newborns of
women with gestational diabetes mellitus (GDM). This ran-
domized, double-blind, placebo-controlled clinical trial was
performed among 40 women with GDM. Patients were ran-
domly allocated to intake either 233 mg zinc gluconate (con-
taining 30 mg zinc) (n = 20) or a placebo (n = 20) for 6 weeks.
PPAR-γ and GLUT1 mRNA levels were quantified in umbil-
ical cord blood of newborns of women with GDM. After
6 weeks of intervention, the change in serum zinc levels was
greater in women consuming zinc than in the placebo group
(+11.1 ± 13.4 vs. −4.8 ± 17.3 mg/dL, P = 0.002). Quantitative
results of RT-PCR demonstrated that compared with the place-
bo, zinc supplementation resulted in a significant increase of
expressed levels of PPAR-γ mRNA (P < 0.001) and GLUT1
mRNA (P < 0.001) in umbilical cord blood of newborns of
women with GDM. Taken together, the current study demon-
strated that zinc supplementation for 6 weeks among GDM
women increased the mRNA levels of PPAR-γ and GLUT1
in their newborns compared with the placebo group.
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Introduction
Gestational diabetes mellitus (GDM) is defined as insulin resis-
tance or carbohydrate intolerance causing hyperglycemia with
onset or first recognition at any time during pregnancy [1].
GDM associated with several maternal complications including
preeclampsia, still birth, and requiring operative vaginal delivery
or cesarean section, as well as several fetal complications such as
prematurity, neonatal hypoglycemia, respiratory distress syn-
drome and hyperbilirubinemia [2]. In addition, hyperglycemia
and altered concentration of fatty acid derivates may result in
decreased expression of peroxisome proliferator-activated recep-
tor gamma (PPAR-γ) in the syncytiotrophoblast and the
extravillous trophoblast of GDM placentas [3]. Previous studies
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